Ashburton Jersey Ltd held its stake in shares of Eli Lilly and Company (NYSE:LLY) during the first quarter, according to its most recent disclosure with the SEC. The fund owned 28,186 shares of the company’s stock at the end of the first quarter. Eli Lilly and accounts for 1.1% of Ashburton Jersey Ltd’s portfolio, making the stock its 17th largest position. Ashburton Jersey Ltd’s holdings in Eli Lilly and were worth $2,371,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of LLY. Vanguard Group Inc. boosted its stake in shares of Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after buying an additional 2,181,701 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after buying an additional 59,978,664 shares during the last quarter. State Street Corp boosted its stake in shares of Eli Lilly and by 1.6% in the first quarter. State Street Corp now owns 42,363,935 shares of the company’s stock worth $3,563,230,000 after buying an additional 651,424 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Eli Lilly and by 8.4% in the first quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock worth $764,597,000 after buying an additional 708,597 shares during the last quarter. Finally, Janus Capital Management LLC boosted its stake in shares of Eli Lilly and by 2.8% in the first quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock worth $733,731,000 after buying an additional 237,619 shares during the last quarter. Institutional investors and hedge funds own 75.59% of the company’s stock.

Shares of Eli Lilly and Company (NYSE:LLY) traded up 0.539% during midday trading on Tuesday, reaching $81.929. 371,381 shares of the company’s stock traded hands. The stock has a market cap of $86.44 billion, a price-to-earnings ratio of 35.452 and a beta of 0.34. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72. The stock has a 50 day moving average of $82.84 and a 200-day moving average of $81.87.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. During the same quarter last year, the business earned $0.86 earnings per share. Eli Lilly and’s revenue was up 7.8% on a year-over-year basis. On average, equities research analysts expect that Eli Lilly and Company will post $4.16 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.55%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s payout ratio is currently 90.04%.

TRADEMARK VIOLATION NOTICE: This piece was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/15/ashburton-jersey-ltd-has-2371000-position-in-eli-lilly-and-company-lly.html.

A number of analysts have recently weighed in on LLY shares. UBS AG cut shares of Eli Lilly and to a “hold” rating and set a $85.00 price objective for the company. in a research note on Wednesday, July 26th. Piper Jaffray Companies restated a “buy” rating and issued a $100.00 price objective on shares of Eli Lilly and in a research note on Monday, April 17th. Argus cut shares of Eli Lilly and from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $64.18 to $81.00 in a research note on Thursday, April 27th. They noted that the move was a valuation call. Jefferies Group LLC restated a “buy” rating and issued a $93.00 price objective on shares of Eli Lilly and in a research note on Thursday, June 22nd. Finally, Sanford C. Bernstein restated an “outperform” rating and issued a $88.00 price objective on shares of Eli Lilly and in a research note on Sunday, May 21st. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $88.27.

In related news, VP Michael J. Harrington sold 22,833 shares of the firm’s stock in a transaction on Friday, June 9th. The stock was sold at an average price of $79.97, for a total value of $1,825,955.01. Following the transaction, the vice president now owns 62,056 shares in the company, valued at $4,962,618.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of the firm’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the transaction, the insider now owns 124,049,283 shares in the company, valued at approximately $10,307,254,924.47. The disclosure for this sale can be found here. Insiders sold 669,733 shares of company stock worth $55,845,287 in the last 90 days. 0.20% of the stock is owned by company insiders.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.